Raziel Therapeutics Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $22.1M
Latest Deal Amount
  • Investors
  • 10

Raziel Therapeutics General Information

Description

Operator of a pharmaceutical firm intended to develop drugs for submental fat, and fat disorders such as Dercum's disease. The company's drug single injection treatment into subcutaneous fat causes immediate fat cell death at the injection site, enabling patients to a significant reduction of fat tissue for long time periods without any invasive procedures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • 10 Prof. Menachem Plaut Street
  • Rehovot
  • Israel
+972 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Raziel Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 18-Dec-2019 $22.1M 000.00 000.00 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series A) 25-Feb-2016 00.00 00.000 000.00 Completed Clinical Trials - Phase 1
2. Early Stage VC 10-Jul-2015 $1.5M $2.09M 00.000 Completed Clinical Trials - Phase 1
1. Early Stage VC 03-Dec-2012 $589K $589K 00.000 Completed Clinical Trials - Phase 1
To view Raziel Therapeutics’s complete valuation and funding history, request access »

Raziel Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred C 000,000 000.00 000.00 00 000.00 00.000
Preferred B2 00,000 0000.00 0000.00 00 0000.00 0.000
Preferred B1 00,000 0000.00 0000.00 00 0000.00 0.000
Preferred A2 00,000 000.00 000.00 00 000.00 0.000
Preferred A1 25,000 $16.67 $16.67 1x $16.67 3.08%
Preferred A 75,000 $7.59 $7.59 1x $7.59 4.61%
To view Raziel Therapeutics’s complete cap table history, request access »

Raziel Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Alon Bloomenfeld Founder, Chief Executive Officer & Board Member
To view Raziel Therapeutics’s complete executive team members history, request access »

Raziel Therapeutics Board Members (9)

Name Representing Role Since
Adi Goldin Self Board Member 000 0000
Alon Bloomenfeld Raziel Therapeutics Founder, Chief Executive Officer & Board Member 000 0000
Eyal Lifschitz Peregrine Ventures Board Member 000 0000
Philippe Schaison Raziel Therapeutics Chairman 000 0000
Shmuel Cabilly Ph.D Self Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Raziel Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Catalyst Fund Impact Investing Minority 000 0000 000000 0
China Everbright Asset Manager Minority 000 0000 000000 0
Peregrine Ventures Venture Capital Minority 000 0000 000000 0
Quark Venture Venture Capital Minority 000 0000 000000 0
Wille Finance Family Office Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »